This multicenter, retrospective cohort study assessed the prognostic ability of the Immunoscore (IS) and the expression of programmed death ligand 1 (PD-L1) or programmed death ligand 2 (PD-L2) to select GC patients at higher risk of recurrence who may therefore require more intensive perioperative treatment.<h4>Methods</h4>In 184 untreated pStage III GC patients who underwent radical gastrectomy at 13 institutions, IS (CD3+ and CD8+ lymphocytes) and PD-L1/2 expression were analyzed by immunohistochemistry using digital pathology HALO software. This evidence concerns the gene CD274 and gastric cancer.